AxoGen (NASDAQ:AXGN) and Vicarious Surgical (NYSE:RBOT) Head-To-Head Review

Vicarious Surgical (NYSE:RBOT) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Vicarious Surgical and AxoGen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
AxoGen	-0.98%	-1.90%	-1.02%

Analyst Ratings

This is a summary of recent ratings and target prices for Vicarious Surgical and AxoGen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1	2	0	0	1.67
AxoGen	1	0	9	0	2.80

Vicarious Surgical currently has a consensus target price of $7.00, indicating a potential upside of 180.56%. AxoGen has a consensus target price of $35.56, indicating a potential upside of 14.70%. Given Vicarious Surgical’s higher possible upside, research analysts clearly believe Vicarious Surgical is more favorable than AxoGen.

Institutional & Insider Ownership

47.3% of Vicarious Surgical shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 10.0% of Vicarious Surgical shares are held by insiders. Comparatively, 2.8% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Vicarious Surgical and AxoGen”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22 million	($9.05)	-0.28
AxoGen	$187.34 million	7.63	-$9.96 million	($0.05)	-620.00

AxoGen has higher revenue and earnings than Vicarious Surgical. AxoGen is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Vicarious Surgical has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.

Summary

AxoGen beats Vicarious Surgical on 8 of the 13 factors compared between the two stocks.

About Vicarious Surgical

Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

About AxoGen

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.